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Abstract
Photodynamic Therapy (PDT) involves the administration of a tumor localizing photosensitizing agent, which upon
activation with light of an appropriate wavelength leads to the destruction of the tumor cells. The aim of the present study
was to determine the efficacy of erythrosine as a photosensitizer for the PDT of oral malignancies. The drug uptake kinetics
of erythrosine in malignant (H357) and pre-malignant (DOK) oral epithelial cells and their susceptibility to erythrosine-based
PDT was studied along with the determination of the subcellular localization of erythrosine. This was followed by initial
investigations into the mechanism of cell killing induced following PDT involving both high and low concentrations of
erythrosine. The results showed that at 37uC the uptake of erythrosine by both DOK and H357 cells increased in an
erythrosine dose dependent manner. However, the percentage of cell killing observed following PDT differed between the 2
cell lines; a maximum of ,80% of DOK cell killing was achieved as compared to ,60% killing for H357 cells. Both the DOK
and H357 cell types exhibited predominantly mitochondrial accumulation of erythrosine, but the mitochondrial trans-
membrane potential (DYm) studies showed that the H357 cells were far more resistant to the changes in DYm when
compared to the DOK cells and this might be a factor in the apparent relative resistance of the H357 cells to PDT. Finally, cell
death morphology and caspase activity analysis studies demonstrated the occurrence of extensive necrosis with high dose
PDT in DOK cells, whereas apoptosis was observed at lower doses of PDT for both cell lines. For H357 cells, high dose PDT
produced both apoptotic as well as necrotic responses. This is the first instance of erythrosine-based PDT’s usage for cancer
cell killing.
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Introduction
Oral cancer is one of the most disfiguring and debilitating
malignancies [1] and an important problem especially in those
countries where tobacco chewing or smoking is prevalent [2]. In
2002, oral cancers accounted for approximately 274,000 cases
world-wide [3]. Surgery, radiation therapy and chemotherapy are
the typical traditional methods used for oral cancer treatment.
Although these traditional oral cancer treatment strategies have
advanced several fold over last few decades (e.g. discovery of new
chemotherapeutics, powerful imaging tools allowing for better
diagnostics-driven surgery and fluorescence/bioluminescence-
guided surgery), the 5-year survival rate for oral cancer victims
hasn’t improved significantly over the past 50 years [4]. In
addition to this, these treatment strategies have several mild to
severe side-effects e.g. salivary gland dysfunction, mucositis/
stomatitis, dental caries/demineralization, neurotoxicity and
osteoradionecrosis [1,4]. Thus, an alternative treatment-strategy
is desirable which could be utilized for treating tumours in the oral
cavity in a simple, efficient, cost-effective and patient-friendly
manner [4]. One such emerging treatment strategy is Photody-
namic Therapy (PDT) [5,6,7].
The principle of PDT is that an administered photosensitizer
(PS) is selectively retained by cancer cells [7] and when the tumour
is irradiated with light of the appropriate wavelength, the PS is
activated and causes tumour cell death by the production of
reactive oxygen species (ROS) and free radicals [7,8,9].
The main cancer-types for which PDT has been widely applied
include malignancies of head and neck, brain, lung, prostate,
ovaries, skin and oesophagus [6,10,11,12]. In the past, PDT has
been applied to oral cancer using various photosensitizers, e.g.,
dihaematoporphyrin, meta tetrahydroxy phenyl chlorine
(mTHPC) or Foscan and 5-aminolaevulinic acid [13]. Though
PDT treatments for oral cancer using the above photosensitizers
are effective there are some limitations [14,15] including the
lengthy clinical and legislative assessments that significantly delay
translation of many such photosensitizers into the clinic. For
instance, while EU has approved usage of Foscan-based PDT for
treatment of early head and neck cancers; FDA has not yet
approved PDT treatment for head and neck squamous cell
carcinoma [4]. Such scenarios, have encouraged the search for
other photosensitizers with more immediate benefits and possibil-
ities of fast clinical translation [15]. To this end, our research has
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34475utilized the photosensitizer, Erythrosine B. Three major advan-
tages of erythrosine over certain other photosensitizers are – (1) it
is not toxic to the host, (2) it is approved by the FDA for usage in
food/food products and (3) it has already been approved for use in
dentistry, thereby making its translation into clinic easier (in case
of promising pre-clinical data) than possible for other photosen-
sitizers, as far as oral cancer is concerned [16,17].
The potential of erythrosine to undergo photochemical
reactions and generate singlet oxygen was known previously [18]
and it has been used by ourselves as a photosensitizer of bio-films
of Streptococcus mutans for the PDT-based cell killing of these oral
infectious bacteria [17]. This suggested that erythrosine may also
be an effective photosensitizing agent for the treatment of cancer
cells [19].
Figure 1. Erythrosine Uptake Analysis. Uptake of erythrosine by pre-malignant (DOK) and malignant (H357) oral epithelial cells was analyzed at
37uC and 4uC. (A) Drug uptake kinetics of erythrosine in DOK cells at 37uC and 4uC. (B) Drug uptake kinetics of erythrosine in H357 cells at 37uC and
4uC. The values are means of four replicate determinations 6 S.E.M. Statistical analysis was done via student’s t-test with significance set at P,0.05 (*
indicates statistical comparison of 37uC data-points vs. the respective data values of 0 mM erythrosine; # indicates comparison of 4uC data-points vs.
the respective data values of 0 mM erythrosine and ** indicates comparison between 37uC data-points and the corresponding 4uC data-points).
doi:10.1371/journal.pone.0034475.g001
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include the cellular uptake kinetics of the photosensitizer and its
subcellular localization characteristics [5,7,9]. Since erythrosine is
a hydrophilic dye [20], it is likely to accumulate preferentially in
lysosomes and mitochondria [21]. These localization characteris-
tics may help in determining the mechanism by which cell death
occurs following PDT.
The site of localization of a PS is usually the primary target for
PDT since the ROS produced due to the PDT have a very short
life-time (,0.05 ms) [5,22,23]. Upon activation using the appro-
priate wavelength of light, the PS absorbs the light photon energy
(h*v) and ascends from ground-state to the excited singlet state
resulting in the production of ROS [7,24]. ROS production due to
PDT causes a highly elevated oxidative stress in the cell, the
magnitude of which depends upon the PDT dose applied and
which also governs the pathway of cell-death following PDT
[6,14,24,25]. The two most well-characterized cell death mech-
anisms following PDT are apoptosis and (primary) necrosis
[5,6,25]. Necrosis usually predominates when using high dose
PDT whereas apoptosis is more usually seen with comparatively
lower PDT doses.
Primary necrosis is principally a passive cell death process which
occurs due to extreme external physical stress or severe
intracellular damage, and is irreversible [21,26].
Apoptosis (programmed cell death), on the other hand, is an
active pathway of cell death which involves the activation of
various cellular factors including initiator caspases (Caspase 2, 8, 9
and 10) and executioner caspases (Caspase 3 and 7) [27].
Apoptotic pathways (intrinsic and extrinsic) usually involve
mitochondria, which is frequently regarded as the central
processing organelle for apoptosis [25,28]. Therefore, mitochon-
drial damage is often essential for the induction of apoptosis within
cells following PDT [7,25].
The aim of the present investigation was to determine the
efficacy of erythrosine in the photodynamic therapy of oral
malignancies. To this end, we have studied the uptake kinetics of
erythrosine in malignant (H357) and pre-malignant (DOK) oral
epithelial cells and their susceptibility to erythrosine-based PDT.
Determination of the subcellular localization of erythrosine was
followed by initial investigations into the mechanism of cell killing
induced at both high and low concentrations of erythrosine.
Results
Erythrosine Uptake Analysis
At 37uC for erythrosine concentrations ranging from 71.03 mM
up to 1136.5 mM, the uptake of erythrosine by DOK cells was seen
to increase in an erythrosine dose-dependent manner, such that it
was significantly more (*P,0.05) for all the erythrosine concen-
trations than the 0 mM background (Figure 1A). A similar uptake
pattern was seen for the H357 cells for erythrosine concentrations
ranging from 71.03 mM to 1136.5 mM (Figure 1B). Statistical
analysis showed that there was no significant difference in the
uptake of erythrosine by the two cell lines at this temperature.
At 4uC the erythrosine uptake was considerably slower,
especially at erythrosine concentrations from 71.03 mMu pt o
568.27 mM (Figure 1A and 1B) for both cell lines. Moreover for
both cell lines (Figure 1A and 1B) at almost all erythrosine
concentrations, the erythrosine uptake at 37uC was significantly
higher than at 4uC (**P,0.05). However, the overall erythrosine
uptake at 4uC was higher for DOK cells (Figure 1A) when
compared to H357 cells (Figure 1B). Similarly, at 1136.5 mM the
erythrosine uptake was significantly higher in DOK cells than in
H357 cells.
PDT based Cell Killing
The overall percentage (%) cell killing caused by PDT in DOK
cells rose in a light/fluence and photosensitizer dose-dependent
manner (Figure 2A). Low PDT doses (all irradiations for
erythrosine concentrations up to 284.13 mM as well as irradiation
of 40.86 J/cm
2 for erythrosine concentrations of 568.27 mM and
1136.5 mM) caused less cell kill which was not significantly higher
than cell killing observed at same erythrosine concentrations
without irradiation (i.e. fluence – 0 J/cm
2). However, at higher
PDT doses (irradiation fluence of 81.72 J/cm
2 and/or 122.58 J/
cm
2 and erythrosine concentrations of 568.27 mM and/or
1136.5 mM) the observed cell kill rose rapidly such that it was
significantly more (*P,0.05) than cell killing observed at same
erythrosine concentrations without irradiation (i.e. fluence – 0 J/
cm
2). The maximum percentage cell kill was observed at
1136.5 mM concentration and 122.58 J/cm
2 irradiation fluence
(Figure 2A). The other dose showing appreciable cell killing was
the 1136.5 mM concentration with 81.72 J/cm
2 irradiation
fluence. Overall, the LD50 for DOK cells was found to be
585.32 mM erythrosine at 122.58 J/cm
2 irradiation fluence and
920.60 mM erythrosine at 81.72 J/cm
2 irradiation fluence.
Cell killing trends following erythrosine-PDT were similar in the
H357 cells (Figure 2B) as described above for DOK cells.
However, cell killing caused by PDT in H357 cells was lower
than in the DOK cells (Figure 2A and 2B). Maximum cell killing
was observed at 1136.5 mM concentration and 122.58 J/cm
2
irradiation fluence (Figure 2B). Overall, the LD50 for PDT-treated
H357 cells was found to be 818.31 mM at 122.58 J/cm
2
irradiation fluence. The LD50 was not reached for the other
irradiation times in H357 cells. Lastly, for erythrosine concentra-
tions above 1136.5 mM( i.e. 2.27–9.09 mM), increasingly signifi-
cant cytotoxicity without irradiation (dark cytotoxicity of the
photosensitizer; data not shown) was observed; hence in the
present study the PDT-analysis has not been performed beyond
the erythrosine concentration of 1136.5 mM. Thus the therapeu-
tically relevant erythrosine concentration range for PDT was less
than 1136.5 mM.
Sub-cellular Localization Analysis by CLSM
Co-localization analysis was carried out for erythrosine with
respect to dyes that stain either lysosomes (LysoTracker) or
mitochondria (MitoTracker). Apart from analysis of merged
channels images, co-localization was also estimated via other
(statistical) parameters like co-localization frequency scatter plots
(based on co-localization frequency colour ‘heat’ maps), Pearson’s
coefficient and Mander’s coefficient, as described elsewhere [29].
In case of both DOK (Figure 3A) and H357 (Figure 3B) cells,
erythrosine was found to co-localize more strongly with Mito-
Tracker than with LysoTracker as indicated by the following four
parameters – (1) higher incidence of yellow co-localization colour
in the merged channels image for MitoTracker/erythrosine, (2)
hotter colours in the co-localization frequency scatter plot (tending
towards 100% co-localization as per the colour map in Figure 3C)
for MitoTracker/erythrosine, (3) higher Pearson’s coefficient
values for MitoTracker/erythrosine (r values, as indicated in the
respective scatter plots) and (4) higher Mander’s coefficient for
MitoTracker/erythrosine (M values, as indicated in the respective
scatter plots).
Based on this data, we can conclude that erythrosine localizes
predominantly in the mitochondria in both the DOK as well as
H357 cell lines.
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Potential (DYm) in DOK and H357 cells
DOK and H357 cells treated with PDT using a low dose of
erythrosine-PDT (71.03 mM erythrosine concentration and
122.58 J/cm
2 irradiation fluence) showed different responses to
the treatment in terms of changes in the DYm. Following low dose
treatment, DOK cells demonstrated a considerable decrease in
their overall DYm immediately following PDT (Figure 4A).
Interestingly, at 2 hrs recovery time, a specific population of cells
Figure 2. Cell Killing Assay. The pre-malignant (DOK) and malignant (H357) oral epithelial cells were incubated with different concentrations of
erythrosine B (71.03 mM, 142.06 mM, 284.13 mM, 568.27 mM and 1136.50 mM) followed by PDT irradiation with different fluences (0 J/cm
2, 40.86 J/
cm
2, 81.72 J/cm
2 and 122.58 J/cm
2). Following PDT, the cells were recovered 24 h later and percentage (%) of cell killing caused by PDT was
estimated. (A) DOK cell’s susceptibility to erythrosine-based PDT and (B) H357 cell’s susceptibility to erythrosine-based PDT. The values are means of
six replicate determinations 6 S.D. Statistical analysis was done via student’s t-test with significance set at P,0.05 (* indicates statistical comparison
of a data-point within one erythrosine B concentration group vs. the corresponding data values of 0 J/cm
2 fluencies for that group).
doi:10.1371/journal.pone.0034475.g002
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However, at 24 hrs, the DYm had collapsed further (Figure 4A).
Low dose-treated H357 cells showed no appreciable loss of their
overall DYm at the earlier recover time-points following PDT
(Figure 4B). However, similar to the DOK cells (Figure 4A), at
24 hrs the DYm suddenly collapsed drastically (Figure 4B).
Similarly, DOK and H357 cells treated with high dose
(1136.5 mM–122.58 J/cm
2) also showed different responses ini-
tially. While DOK cells immediately lost their DYm after PDT
(Figure 4A), the H357 cells initially resisted the change in DYm at
the earlier recovery time-points after PDT (Figure 4B). However,
at 24 hrs after PDT, the DYm collapsed drastically for both cell
lines thereby pointing towards severe mitochondrial outer-
membrane permeabilization (MMP).
Cell Death Morphology analysis using CLSM and SEM
Untreated (Control) DOK and H357 cells showed a normal
morphology in both the SEM (Figure 5 and 6) and CLSM analyses
(Figure 7). Following PDT with low dose erythrosine-PDT
(71.03 mM–122.58 J/cm
2), we observed apoptotic-like character-
istics such as membrane blebbing, cell shrinkage, loss of extensive
cell-cell linkage and formation of apoptotic bodies at early
recovery time points post-PDT (0–4 h) followed by secondary
necrosis at 24 h post-PDT; in both DOK (Figure 5 and 7) and
H357 cells (Figure 6 and 7). Following PDT with high dose
erythrosine-PDT (1136.5 mM–122.58 J/cm
2) we observed prom-
inent necrotic characteristics such as extensive membrane and cell
disintegration, extensive karyolysis and the presence of large
amounts of cellular debris at all recovery time point post-PDT in
DOK cells (Figure 5 and 7) along with some apoptotic
characteristics in H357 cells (Figure 6 and 7).
Caspase Activity Assay
Untreated (Control) DOK and H357 cells showed a constant,
basal caspase 3/7 activity at all recovery time points. But after a
low dose of erythrosine-PDT (71.03 mM–122.58 J/cm
2), we
observed an increase in the caspase 3/7 activity in both the cell
lines (Figure 8A and 8B). The caspase 3/7 activity initially
Figure 3. Erythrosine co-localization analysis. Sub-cellular co-localization of erythrosine in both DOK and H357 cells. (A and B) LysoTracker
localization (for lysosomal visualization) and MitoTracker localization (for mitochondrial visualization) was compared with 1136.50 mM erythrosine
localization in both DOK (A) as well as H357 (B) cells. Also, co-localization frequency scatter plots, Pearson’s coefficient (r) and Mander’s coefficient (M)
were calculated to evaluate the overlap between LysoTracker/MitoTracker localizations and erythrosine localizations. (C) Co-localization frequency
colour map indicates the estimation of co-localizations on the basis of ‘heat map schemes’ such that hotter colours tend to indicate high co-
localization. Thus, red/maroon indicates 100% co-localization, yellow-green indicates 50% co-localization and purple/dark blue indicates 0% co-
localization.
doi:10.1371/journal.pone.0034475.g003
Erythrosine-Based PDT of Oral Epithelial Cells
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e34475increased in the early recovery time points (Figure 8) and returned
back to the control levels by 24 hr after treatment suggesting the
occurrence of caspase-dependent apoptosis at early recovery time
point culminating into secondary necrosis following PDT. This
confirms the results seen with CLSM and SEM studies. Following
high dose erythrosine-PDT (1136.5 mM–122.58 J/cm
2), DOK
cells showed caspase 3/7 activity below the control levels
suggesting the occurrence of necrosis (Figure 8A). Again this
confirms the results obtained with the CLSM and SEM studies.
Contrary to this, the H357 cells showed an increase in caspase 3/7
activity following high PDT dose treatment suggesting the
occurrence of apoptosis and a more limited necrotic response
(Figure 8B). This limited necrotic response of H357 cells might go
some way toward explaining the apparent resistance of these cells
to erythrosine-PDT.
Discussion
In common with other therapeutic strategies, PDT is constantly
evolving and continues to be improved further [7,30]. A defining
feature of the development of PDT is the discovery of newer and
more powerful photosensitizers [5,14,30]. To this end we have
been investigating Erythrosine B as a potential photosensitizer for
PDT-based treatment of oral malignancies.
The concentration of photosensitizer (PS) taken up by the cells is
a vital parameter in cell killing efficacy [30]. Erythrosine uptake in
DOK and H357 cells increased in an erythrosine concentration-
dependent manner. In addition, the overall uptake was higher at
37uC than at 4uC suggesting that both active and passive uptake
pathways are operating. Cells usually take up chemicals/drugs
through either passive diffusion or through active transport [31]
usually in association with various serum proteins such as
lipoproteins, albumin and globulins [32] or by pinocytosis
especially via bovine/calf serum albumin [33]. Lower temperatures
affect lipid membrane structure [34] thereby preventing active
transport of drugs into the cell [35]. Thus at 4uC, passive transport
is usually predominant.
DOK and H357 cells showed a dose-dependent response to the
PDT treatment. Maximum cell killing was observed at 1136.5 mM
erythrosine and 122.58 J/cm
2 irradiation fluence in DOK
(,80%) as well as H357 (,60%) cells. It is apparent that DOK
Figure 4. Mitochondrial trans-membrane potential analysis. Effects of PDT on mitochondrial trans-membrane potential (DYm) at different
recovery time points post-PDT (0, 2 and 24 h) on DOK and H357 cells were analyzed at both low (71.03 mM) and high (1136.50 mM) doses of
erythrosine. For both doses, PDT irradiation was done with a fluence of 122.58 J/cm
2. A, DYm studies on DOK cells at low (71.03 mM–122.58 J/cm
2)
and high (1136.50 mM–122.58 J/cm
2) doses of erythrosine-PDT. B, DYm studies on H357 cells at low (71.03 mM–122.58 J/cm
2) and high (1136.50 mM–
122.58 J/cm
2) doses of erythrosine-PDT. The presented histograms are representative of three replicate determinations.
doi:10.1371/journal.pone.0034475.g004
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based PDT than H357 (malignant) cells. This difference in
susceptibility to PDT could be occurring for various reasons. One
possible reason is the expression of telomerase which promotes cell
survival by protecting cells from apoptosis [36,37,38]. Other
protective mechanisms that might play a role in the resistance of
H357 cells to erythrosine-based PDT include; (1) induction of
drug-detoxifying mechanisms, (2) resistance to drug-induced
apoptosis [39], (3) Mutational difference between DOK and
H357 cells (p53 and Ha-ras gene is mutated in H357 cells) and (4)
increased expression of anti-oxidants. Further, it was noted that for
low PDT-doses, the standard deviation was large whereas for high
PDT-doses the data spread was much lower. This variability in
data might be explained by the fact that low PDT-stress resulting
from low dosage has the ability of inducing several different
responses in the treated cells e.g. apoptosis, repair, survival tactics
and autophagy, while high PDT-stress results in induction of quick
responses such as necrosis [21].
Erythrosine was found to be predominantly localizing in the
mitochondria, for DOK as well as H357 cell types. We therefore
attempted to find out whether erythrosine-based PDT causes any
change in the mitochondrial trans-membrane potential (Dym).
Our results showed that the H357 cells are far more resistant to
changes in Dym when compared to the DOK cells. Dissipation of
Dym in DOK cells was observed with both high and low doses of
erythrosine which suggests it as a primary result of PDT-induced
damage. However, there was less variation in the Dym of H357
cells where both the high and low doses produced a shift in
potential only at the 24 hr recovery time point. This suggests that
in the H357 cells there is a mechanism occurring at the cellular
level which is capable of rescuing the cells from the effect of PDT.
The precise mechanism by which depletion of Dym is causing cell
death is unclear, but it has been reported that the dissipation of
Dym will actually cause the release of cytochrome c and activate
apoptosis [40,41]. Other reports conclude that there is no
relationship between Dym and release of cytochrome c along
with apoptosis [42]. Nevertheless, our data suggests that the
dissipation of Dym following PDT has significantly deleterious
effects on cell survival. Interestingly, it has also been reported
previously that the dissipation in Dym actually enhances the
permeability of lysosomal membranes, resulting in the release of
lysosomal proteins and subsequent activation of cell death
pathways accompanied by autophagy [43].
Figure 5. Scanning Electron Microscopy (SEM) Analysis on DOK cells. SEM images showing DOK cell morphologies at different recovery time
points post-PDT (0, 2 and 24 h) were taken for both low (71.03 mM) and high (1136.50 mM) doses of erythrosine. For both doses, PDT irradiation was
done with a fluence of 122.58 J/cm
2. These images demonstrate the occurrence of apoptosis (and secondary necrosis) following PDT with low dose
erythrosine and necrosis in the high dose condition.
doi:10.1371/journal.pone.0034475.g005
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demonstrated the occurrence of apoptosis following low dose
PDT and necrosis with high dose in both the celllines. In H357 cells
high dose PDT induced apoptosis in addition to necrosis. It has
been reported previously by Castano et al that higher doses of PDT
result predominantly in necrosis depending upon the cell line and
the low dose in PDT results in apoptosis [44]. Kessel et al have also
reported the higher incidence of apoptosis during low dose PDT
and inhibition of apoptosis at high dose with aluminum phthalo-
cyanine chloride and two other porphycene sensitizers [45].
This is confirmed by the results of the caspase 3/7 activity
analysis presented in this study which suggested the occurrence of
apoptosis following low dose PDT in both cell lines during the
initial recovery time points. An increase in caspase 3/7 activity was
also seen using high dose PDT in H357 cells suggesting the
occurrence of apoptosis alongside necrosis in this cell line.
As expected, high dose PDT of DOK cells resulted in caspase
3/7 activity below control levels which is supported by the SEM/
CLSM data and suggests that necrosis is the main mechanism of
cell death at this dose. This occurrence of extensive necrosis in the
DOK cells is probably the main reason for the higher death
percentage in DOK cells when compared to the H357 cells. Kessel
et al (1997) and Shah et al (1996) have reported that extensive
necrosis is promoted when there is an increased photo-inactivation
of caspases and inhibition of apoptosis [45,46]. The result of this
study has shown us that the H357 are far more resistant than the
DOK cells.
To conclude, we have found that erythrosine is an effective
photosensitizer for PDT treatment of both malignant and pre-
malignant oral cell lines. In fact, to the best of our knowledge, this
is the first instance of erythrosine-based PDT being applied to kill
cancer cells. However, the malignant H357 cell line was more
resistant to PDT which may be related to a lower necrotic
response following PDT. Further studies are needed to elucidate
the precise mechanisms of cell killing at a molecular level.
Moreover it would be also vital in the near future, to analyze if
erythrosine offers better pharmacokinetics and physio-chemical
properties than existing photosensitizers.
Materials and Methods
Cell Culture Conditions
The two oral epithelial cell lines (DOK and H357) were
purchased from the European Collection of Cell Cultures
Figure 6. Scanning Electron Microscopy (SEM) Analysis on H357 cells. SEM images showing H357 cell morphologies at different recovery
time points post-PDT (0, 2 and 24 h) were taken for both low (71.03 mM) and high (1136.50 mM) doses of erythrosine. For both doses, PDT irradiation
was done with a fluence of 122.58 J/cm
2. These images demonstrate the occurrence of apoptosis (and secondary necrosis) following PDT with low
dose erythrosine and necrosis in the high dose condition.
doi:10.1371/journal.pone.0034475.g006
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and H357 (malignant; ECACC No. 06092004) [48] cells were
derived from dysplastic oral keratinocytes and squamous cell
carcinoma (SCC) of the tongue respectively. Both cell lines were
cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Sigma-
Aldrich, UK) supplemented with 10% Fetal Calf Serum (Sigma-
Aldrich, UK), 50 U/ml of Penicillin-Streptomycin (Sigma-Al-
drich, UK) and 5 mg/ml of Hydrocortisone (Sigma-Aldrich, UK)
and maintained at 37uC with 5% CO2 atmosphere.
Preparation of Erythrosine
Erythrosine B sodium salt (Sigma-Aldrich, UK) was dissolved in
DMEM to give a final concentration of 1 mg/ml. This solution was
then sterilized using a 0.2 mm filter and serially diluted to produce
photosensitizer concentrations of 0.5 mg/ml, 0.25 mg/ml,
0.125 mg/ml and 0.0625 mg/ml for use in the following studies.
Light Source:-
A 400W Tungsten filament lamp with a fluence rate of
22.7 mWcm
22 in the 500–550 nm wavelength range was used for
illumination of samples. A water tank was used to remove infra-
red. Samples were placed under the water tank at a distance of
30 cm from the lamp during irradiation. The irradiance was
calculated under the water tank at a distance of 30 cm from the
lamp (treatment location). Throughout this study, control samples
are cells incubated with erythrosine B but not irradiated (i.e.
untreated samples).
Erythrosine Uptake Analysis
DOK and H357 cells were seeded in 6-well plates (10
4 cells/
well) and returned to the incubator overnight. The cells were then
incubated with erythrosine at concentrations of 0.0625 mg/ml
(71.03 mM), 0.125 mg/ml (142.06 mM), 0.25 mg/ml (284.13 mM),
0.5 mg/ml (568.27 mM) and 1 mg/ml (1136.5 mM) at 37uCo ra t
4uC for 30 min. The cells were then washed (63) with Dulbecco’s
Phosphate Buffer Saline (PBS), incubated with 0.1 M NaOH
(1 ml, for 1–2 min) and harvested using a cell scraper. The
samples were then diluted (1:10) with 0.1 M NaOH followed by
determination of fluorescence intensity using an excitation
(550 nm) and emission (540 nm) wavelength in the Microplate
Reader (Dynex Technologies Ltd, UK). Erythrosine concentration
Figure 7. Confocal Laser Scanning Microscopy (CLSM) Analysis. CLSM images of DOK (A) and H357 (B) cells at different recovery time points
post-PDT (2, 4 and 24 h) were taken for both low (71.03 mM) and high (1136.50 mM) doses of erythrosine. For both doses, PDT irradiation was done
with a fluence of 122.58 J/cm
2. Green (SYTO9) fluorescence represents both live and dead cells while red (Propidium Iodide) fluorescence stains the
dead cells alone. The arrow in the DOK cells (A) indicates the presence of apoptotic bodies whereas the arrow in the H357 cells (B) points to a group
of necrotic cells.
doi:10.1371/journal.pone.0034475.g007
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fluorescence with that of a standard erythrosine solution in 0.1 M
NaOH. The amount of protein in each sample was also
determined using the BCA (bicinchoninic acid) Protein Assay
Kit (Pierce, UK), as per the manufacturer’s instructions. All
erythrosine uptake experiments were carried out in quadruplicate
for each treated and control sample. Erythrosine uptake was
expressed as mg erythrosine/mg cell protein.
PDT based Cell Killing
DOK and H357 cells were plated in 96-well plates (5610
3 cells/
well) 24 hours before the treatment. Duplicate wells were incubated
with erythrosine concentrations of 0.0625 mg/ml (71.03 mM),
0.125 mg/ml (142.06 mM), 0.25 mg/ml (284.13 mM), 0.5 mg/ml
(568.27 mM) and 1 mg/ml (1136.5 mM) for 30 min. Cell monolay-
ers were then washed (63 with PBS) and subjected to PDT using 0,
30 (40.86 J/cm
2), 60 (81.72 J/cm
2) and 90 (122.58 J/cm
2) min
irradiation times (fluences). After irradiation, plates were incubated
at 37uC for 12 hr before quantification of cell viability using the
CellTiter 96HAQueous One Solution Cell Proliferation Assay
(Promega, USA) as per the manufacturer’s instructions. Formazan
formed by viable cells was quantified by reading the plates at
490 nm using a Microplate Reader (Dynex Technologies Ltd.,
UK).CellkillfollowingPDTwereconverted intopercentagecellkill
using the following formulae:
Figure 8. Caspase 3/7 Activity Assay. Caspase 3/7 activation in response to PDT was estimated at four different recovery time points post-PDT (0,
2, 4 and 24 hr) in DOK (A) and H357 cells (B) at both low (71.03 mM) and high (1136.50 mM) doses of erythrosine. For both doses, PDT irradiation was
done with a fluence of 122.58 J/cm
2. In order to bring the data sets of both DOK and H357 cells to the same scale, the luminometer arbitrary values
for DOK cells were divided by 10. The values are means of three replicate determinations 6 S.D. Statistical analysis was done via student’s t-test with
significance set at P,0.05 (* indicates statistical comparison as indicated by the lines).
doi:10.1371/journal.pone.0034475.g008
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(A490 Control Cells{A490 Treated Cells)=A490 Control Cells
Sub-cellular Localization Analysis by CLSM
DOK and H357 cells were seeded in Sterilin Petri-dish.
Following attachment they were incubated with a concentration
of 1136.5 mM erythrosine at 37uC for 30 min in the dark. For
organelle localization comparison, cells were either co-incubated
with 100 nM LysoTracker Green (Invitrogen) or 100 nM
MitoTracker Green (Invitrogen). Samples were then observed
directly using a Leica TCS SP2 Confocal Laser Scanning
Microscope (CLSM). All the images were analyzed via ImageJ
software (W. S. Rasbaud, Image J, NIH, Bethesda, MD, http://
rsb.info.nih.gov/ij/). Co-localization of either LysoTracker or
MitoTracker with erythrosine was (statistically) evaluated through
the agency of co-localization frequency scatter plots, Pearson’s
coefficient and Mander’s coefficient as explained elsewhere [29].
Mitochondrial Trans-Membrane Potential (DYm) Analysis
via Flow Cytometry
DOK and H357 cells were seeded in 21.5 cm
2 cell culture
plates as described above. Following incubation with erythrosine
concentrations of 0.0625 mg/ml (71.03 mM) and 1 mg/ml
(1136.5 mM) for 30 min, the cells were irradiated for 90 min
(122.58 J/cm
2). Cells were then trypsinised at three different
recovery time-points (0, 2 and 24 h) after irradiation followed by
cell pelleting and washing with PBS. The cell pellet was then
resuspended in PBS containing 5 mg/ml of Rhodamine B followed
by incubation for 30 min at 37uC. Subsequently, the cells were
analyzed using the FACS Calibur Flow Cytometry (BD Biosci-
ences, USA). The results were processed using CellQuest Software
(BD Biosciences, USA). For each sample, 10,000 events were
collected. The results generated by CellQuest software were
processed using the software, WinMDI v.2.9 (http://facs.scripps.
edu/software.html). Here, the intensity of rhodamine B fluores-
cence was taken as direct indication of overall mitochondrial
membrane potential (DYm) for a particular cell population. All the
calibrations of the flow cytometer were set-up by Dr. Gareth
Howell (Research Fellow, Institute of Molecular and Cellular
Biology, Faculty of Biological Sciences, University of Leeds, UK).
Cell Death Morphology Analysis using Scanning Electron
Microscopy (SEM)
DOK and H357 cells were prepared as stated above in
21.5 cm
2 cell culture plates for two different erythrosine
concentrations 20.0625 mg/ml (71.03 mM) and 1 mg/ml
(1136.5 mM). Following incubation with erythrosine, the cells
were irradiated for 90 min (122.58 J/cm
2) followed by fixation for
1 hr using 2.5% gluteraldehyde in PBS (pH 7.4) at three different
recovery time-points (0,2 and 24 h) after irradiation. Subsequently,
the cells were washed with PBS (36) to ensure complete
gluteraldehyde removal. Samples were then dehydrated through
a graded ethyl alcohol series. Following dehydration, the plates
were cut into suitable pieces, fixed to aluminum stubs and sputter-
coated with gold using an Automatic Sputter Coater (Agar
Scientific, UK). The samples were then visualized directly using a
Hitachi VP-SEM S-3400N Scanning Electron Microscope.
Cell Death Morphology Analysis using CLSM
DOK and H357 cells were prepared as stated above in
21.5 cm
2 cell culture plates for two different erythrosine
concentrations 20.0625 mg/ml (71.03 mM) and 1 mg/ml
(1136.5 mM) and subjected to PDT 290 min irradiation
(122.58 J/cm
2). Following PDT, the cells were stained using
SYT09 stain (green fluorescence; excitation l- 420 nm, emission
l-580 nm) which stains the nucleic acid in both live/dead cells and
Propidium Iodide (PI) (red fluorescence; excitation l- 420 nm,
emission l-580 nm) which stains the nucleic acids of dead cells
alone; at recovery time points of 2, 4 and 24 h following
irradiation. Cells were then observed immediately using a Leica
TCS SP2 CLSM.
Caspase Activity Assay
Samples were prepared as stated above in 96-well plate for two
different erythrosine concentrations 20.0625 mg/ml (71.03 mM)
and 1 mg/ml (1136.5 mM) and subjected to PDT 290 min
irradiation (122.58 J/cm
2). Following PDT, the Caspase activity
assay was performed using the Caspase-Glo3/7 assay (Promega,
Madison, USA) kit at four different recovery time point (0, 2, 4
and 24 h) as per the manufacturer’s instruction. Then the plates
were observed for the luminescence signal in the luminometer
(BMG Labtech Fluostar Optima, Germany). Calibrations of the
luminometer were performed by Dr. Carsten Zoothner (Techni-
cian, Institute of Molecular and Cellular Biology, University of
Leeds, UK).
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